Charles Schwab Investment Management Inc. decreased its stake in DaVita Inc. (NYSE:DVA - Free Report) by 2.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 489,257 shares of the company's stock after selling 12,344 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.60% of DaVita worth $73,168,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new stake in DaVita during the 4th quarter worth about $41,000. Quarry LP acquired a new stake in DaVita during the 3rd quarter worth about $60,000. Venturi Wealth Management LLC boosted its position in DaVita by 59.8% during the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after acquiring an additional 152 shares during the period. Versant Capital Management Inc boosted its position in DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $68,000 after acquiring an additional 169 shares during the period. Finally, Blue Trust Inc. boosted its position in DaVita by 39.7% during the 4th quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after acquiring an additional 131 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.
DaVita Stock Down 3.4 %
Shares of DaVita stock opened at $146.71 on Wednesday. The firm has a market cap of $11.74 billion, a price-to-earnings ratio of 13.66, a P/E/G ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 52-week low of $125.64 and a 52-week high of $179.60. The stock has a 50-day simple moving average of $159.41 and a 200-day simple moving average of $157.90.
DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, equities research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the company. Barclays raised their price objective on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on DaVita in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $166.33.
View Our Latest Stock Report on DVA
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
